If you were around when they stuffed PBT2 because the trial was badly designed, the delay to have a more robust structure is a very good thing.
The design of a trial is one of the major assessment points for PE investors in their approach
Ann: Expanded ATH434 Phase 2 Clinical Development Program, page-8
-
- There are more pages in this discussion • 22 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
-0.001(11.1%) |
Mkt cap ! $20.98M | |||
| Open | High | Low | Value | Volume |
| 0.5¢ | 0.5¢ | 0.4¢ | $14.55K | 3.241M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 62 | 71906262 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 32338803 | 25 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| ATH (ASX) Chart |